Your browser doesn't support javascript.
loading
Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk.
Kapoor, Pooja Middha; Mavaddat, Nasim; Choudhury, Parichoy Pal; Wilcox, Amber N; Lindström, Sara; Behrens, Sabine; Michailidou, Kyriaki; Dennis, Joe; Bolla, Manjeet K; Wang, Qin; Jung, Audrey; Abu-Ful, Zomoroda; Ahearn, Thomas; Andrulis, Irene L; Anton-Culver, Hoda; Arndt, Volker; Aronson, Kristan J; Auer, Paul L; Freeman, Laura E Beane; Becher, Heiko; Beckmann, Matthias W; Beeghly-Fadiel, Alicia; Benitez, Javier; Bernstein, Leslie; Bojesen, Stig E; Brauch, Hiltrud; Brenner, Hermann; Brüning, Thomas; Cai, Qiuyin; Campa, Daniele; Canzian, Federico; Carracedo, Angel; Carter, Brian D; Castelao, Jose E; Chanock, Stephen J; Chatterjee, Nilanjan; Chenevix-Trench, Georgia; Clarke, Christine L; Couch, Fergus J; Cox, Angela; Cross, Simon S; Czene, Kamila; Dai, James Y; Earp, H Shelton; Ekici, Arif B; Eliassen, A Heather; Eriksson, Mikael; Evans, D Gareth; Fasching, Peter A; Figueroa, Jonine.
Afiliación
  • Kapoor PM; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Mavaddat N; Faculty of Medicine, University of Heidelberg, Heidelberg, Germany.
  • Choudhury PP; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Wilcox AN; Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Lindström S; Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Behrens S; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Michailidou K; Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA.
  • Dennis J; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Bolla MK; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Wang Q; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Jung A; Biostatistics Unit and the Cyprus, School of Molecular Medicine, Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
  • Abu-Ful Z; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Ahearn T; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Andrulis IL; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Anton-Culver H; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Arndt V; Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.
  • Aronson KJ; Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Auer PL; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
  • Freeman LEB; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  • Becher H; Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
  • Beckmann MW; Division of Clinical Epidemiology and Aging Research, C070, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Beeghly-Fadiel A; Department of Public Health Sciences and Cancer Research Institute, Queen's University, Kingston, ON, Canada.
  • Benitez J; Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Bernstein L; Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
  • Bojesen SE; Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Brauch H; Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Brenner H; Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Brüning T; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Cai Q; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Campa D; Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  • Canzian F; Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Carracedo A; Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.
  • Carter BD; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Castelao JE; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Chanock SJ; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Chatterjee N; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Chenevix-Trench G; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Clarke CL; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Couch FJ; Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Cox A; iFIT-Cluster of Excellence, University of Tuebingen, Tuebingen, Germany.
  • Cross SS; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Czene K; Division of Clinical Epidemiology and Aging Research, C070, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Dai JY; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Earp HS; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Ekici AB; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany.
  • Eliassen AH; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Eriksson M; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Evans DG; Department of Biology, University of Pisa, Pisa, Italy.
  • Fasching PA; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Figueroa J; Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
J Natl Cancer Inst ; 113(3): 329-337, 2021 03 01.
Article en En | MEDLINE | ID: mdl-32359158
ABSTRACT
We evaluated the joint associations between a new 313-variant PRS (PRS313) and questionnaire-based breast cancer risk factors for women of European ancestry, using 72 284 cases and 80 354 controls from the Breast Cancer Association Consortium. Interactions were evaluated using standard logistic regression and a newly developed case-only method for breast cancer risk overall and by estrogen receptor status. After accounting for multiple testing, we did not find evidence that per-standard deviation PRS313 odds ratio differed across strata defined by individual risk factors. Goodness-of-fit tests did not reject the assumption of a multiplicative model between PRS313 and each risk factor. Variation in projected absolute lifetime risk of breast cancer associated with classical risk factors was greater for women with higher genetic risk (PRS313 and family history) and, on average, 17.5% higher in the highest vs lowest deciles of genetic risk. These findings have implications for risk prevention for women at increased risk of breast cancer.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: J Natl Cancer Inst Año: 2021 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: J Natl Cancer Inst Año: 2021 Tipo del documento: Article País de afiliación: Alemania